Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials

Luca Laurenti, Sofia Galimberti, Francesco Morabito, Federica Maria Rossi, Paolo Monti, Dario Rossi, Robin Foa, Marino Gentile, Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Marta Coscia, Yair Herishanu, Sabrina Bossio, Marzia Varettoni, Roberta Murru, Annalisa ChiarenzaAndrea Visentin, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Francesca Maria Rossi, Antonella Zucchetto, Hamdi Al-Janazreh, Ernesto Vigna, Enrica Antonia Martino, Ramona Cassin, Graziella D′Arrigo, Sara Galimberti, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Antonino Neri, Gilberto Fronza, Paola Monti, Paola Menichini, Jacopo Olivieri, Giovanna Cutrona, Davide Rossi, Antonio Cuneo, Francesco Di Raimondo, Gianluca Gaidano, Aaron Polliack, Livio Trentin, Robin Foà, Manlio Ferrarini, Valter Gattei, Massimo Gentile

Research output: Contribution to journalArticle

Abstract

n/a
Original languageEnglish
Pages (from-to)E269-E272
JournalAmerican Journal of Hematology
Volume96
DOIs
Publication statusPublished - 2021

Keywords

  • Adenine
  • Aged
  • Bendamustine Hydrochloride
  • Rituximab
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Piperidines
  • Progression-Free Survival
  • Humans

Fingerprint

Dive into the research topics of 'Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials'. Together they form a unique fingerprint.

Cite this